Preoperative use of raltegravir-containing regimen as induction therapy: Very rapid decline of HIV-1 viral load

AIDS

Volumn 23, Issue 6, 2009, Pages 739-

  Papendorp, Stephan Gerardus ^a   Van Den Berk, Guido E ^a  

^a Onze Lieve Vrouwe Gasthuis ^*  (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; EFAVIRENZ; EMTRICITABINE; PENICILLIN G; RALTEGRAVIR; TENOFOVIR;

ADULT; BACTERIAL ENDOCARDITIS; BACTERIAL MENINGITIS; CASE REPORT; DRUG MEGADOSE; DRUG WITHDRAWAL; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INTERSTITIAL LUNG DISEASE; LETTER; LUNG BIOPSY; MAINTENANCE THERAPY; MALE; MITRAL VALVE REGURGITATION; MITRAL VALVE REPLACEMENT; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIAE; TRICUSPID VALVE REGURGITATION; TRICUSPID VALVE REPLACEMENT; VIRUS INHIBITION; VIRUS LOAD; VIRUS REPLICATION;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; HIV INFECTIONS; HIV INTEGRASE INHIBITORS; HIV-1; HUMANS; MIDDLE AGED; PREOPERATIVE CARE; PYRROLIDINONES; VIRAL LOAD;

EID: 64549143423     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328325a4bd     Document Type: Letter

References (5)

1. Castella A, Vallino A, Argentero PA, Zotti CM. Preventability of percutaneous injuries in healthcare workers: a year-long survey in Italy. J Hosp Infect 2003; 55:290-294.
2. Regez RM, Speekenbrink RC, Landsaat PM, Vahl AC, Kleipool AE, Frissen PH. Safety regarding invasive procedures in HIV- positive patients [in Dutch]. Ned Tijdschr Ceneeskd 2002; 146:601-603.
3. Markowitz M, Nguyen BY, Gotuzzo E, Mendo F, Ratanasuwan W, Kovacs C, et al. Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr 2007; 46:125-133.
4. Grinsztejn B, Nguyen BY, Katlama C, Gatell JM, Lazzarin A, Vittecoq D, et al. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet 2007; 369:1261-1269.
5. Sedaghat AR, Dinoso JB, Shen L, Wilke CO, Siliciano RF. Decay dynamics of HIV-1 depend on the inhibited stages of the viral life cycle. Proc Natl Acad Sci USA 2008; 105:4832-4837.